CCM
UTHR icon

Chilton Capital Management’s United Therapeutics UTHR Stock Holding History

Chilton Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$542 Sell
1
-9
-90% -$5.07K ﹤0.01% 573
2026
Q1 		$5.93K Buy
+10
New +$4.98K ﹤0.01% 530
2024
Q2 		– Sell
-3
Closed -$690 – 677
2024
Q1 		$690 Buy
+3
New +$677 ﹤0.01% 579
2022
Q3 		– Sell
-49
Closed -$12K – 599
2022
Q2 		$12K Buy
+49
New +$9.96K ﹤0.01% 450
2022
Q1 		– Sell
-67
Closed -$14K – 594
2021
Q4 		$14K Buy
+67
New +$13.2K ﹤0.01% 461

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Chilton Capital Management's UTHR Position: Q2 2026 in Review

Chilton Capital Management reduced its United Therapeutics (UTHR) stake by 90% in Q2 2026, selling an estimated $5.07K and leaving 1 share worth $542. The position accounts for ﹤0.01% of the portfolio, ranked #573.

Chilton Capital Management first reported a position in UTHR in Q4 2021 and has held it in 5 quarters since. The position peaked at $14K in Q4 2021. 875 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Chilton Capital Management held 1 share of United Therapeutics worth $542 as of Q2 2026.
  • Chilton Capital Management sold 9 United Therapeutics shares in Q2 2026, an estimated $5.07K.
  • United Therapeutics made up ﹤0.01% of Chilton Capital Management's portfolio in Q2 2026, its #573 holding.
  • Chilton Capital Management first reported a position in United Therapeutics in Q4 2021 and has held it in 5 quarters since.
  • Chilton Capital Management's United Therapeutics position peaked at $14K in Q4 2021.
  • 875 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Chilton Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.